Survey of antimicrobial resistance in clinical Burkholderia pseudomallei isolates over two decades in Northeast Thailand

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 11, 2011, Pages 5388-5391

  Wuthiekanun, Vanaporn ^a   Amornchai, Premjit ^a   Saiprom, Natnaree ^a   Chantratita, Narisara ^a   Chierakul, Wirongrong ^a   Koh, Gavin C K W ^a,d   Chaowagul, Wipada ^b   Day, Nicholas P J ^a,c   Limmathurotsakul, Direk ^a   Peacock, Sharon J ^a,d  

^a MAHIDOL UNIVERSITY   (Thailand)

^b Sappasitthiprasong Hospital   (Thailand)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; CEFTAZIDIME; IMIPENEM; MEROPENEM;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BURKHOLDERIA PSEUDOMALLEI; CLINICAL ARTICLE; GENOTYPE; HUMAN; MELIOIDOSIS; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; THAILAND;

AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-BACTERIAL AGENTS; BURKHOLDERIA PSEUDOMALLEI; CEFTAZIDIME; DRUG RESISTANCE, BACTERIAL; HUMANS; IMIPENEM; MELIOIDOSIS; THAILAND; THIENAMYCINS;

EID: 80054710806     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05517-11     Document Type: Article

References (23)

1. Chaowagul, W., Y. Suputtamongkul, M. D. Smith, and N. J. White. 1997. Oral fluoroquinolones for maintenance treatment of melioidosis. Trans. R. Soc. Trop. Med. Hyg. 91:599-601. (Pubitemid 27478659)
2. Cheng, A. C., et al. 2007. A randomized controlled trial of granulocyte colony-stimulating factor for the treatment of severe sepsis due to melioidosis in Thailand. Clin. Infect. Dis. 45:308-314. (Pubitemid 47101026)
3. Chetchotisakd, P., W. Chaowagul, P. Mootsikapun, D. Budhsarawong, and B. Thinkamrop. 2001. Maintenance therapy of melioidosis with ciprofloxacin plus azithromycin compared with cotrimoxazole plus doxycycline. Am. J. Trop. Med. Hyg. 64:24-27. (Pubitemid 32550093)
4. Chierakul, W., et al. 2005. Two randomized controlled trials of ceftazidime alone versus ceftazidime in combination with trimethoprim- sulfamethoxazole for the treatment of severe melioidosis. Clin. Infect. Dis. 41:1105-1113. (Pubitemid 41429472)
5. Clinical and Laboratory Standards Institute. 2010. Performance standards for antimicrobial susceptibility testing; twentieth informational supplement. M100-S20, vol. 30(1), p. 40-53. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Currie, B. J., L. Ward, and A. C. Cheng. 2010. The epidemiology and clinical spectrum of melioidosis: 540 cases from the 20 year Darwin prospective study. PLoS Negl. Trop. Dis. 4:e900.
7. Dance, D. A., V. Wuthiekanun, W. Chaowagul, and N. J. White. 1989. The antimicrobial susceptibility of Pseudomonas pseudomallei. Emergence of resistance in vitro and during treatment. J. Antimicrob. Chemother. 24:295-309. (Pubitemid 19238292)
8. Godoy, D., et al. 2003. Multilocus sequence typing and evolutionary relationships among the causative agents of melioidosis and glanders, Burkholderia pseudomallei and Burkholderia mallei. J. Clin. Microbiol. 41:2068-2079. (Pubitemid 36576536)
9. Inglis, T. J., F. Rodrigues, P. Rigby, R. Norton, and B. J. Currie. 2004. Comparison of the susceptibilities of Burkholderia pseudomallei to meropenem and ceftazidime by conventional and intracellular methods. Antimicrob. Agents Chemother. 48:2999-3005. (Pubitemid 38989167)
10. Jenney, A. W., G. Lum, D. A. Fisher, and B. J. Currie. 2001. Antibiotic susceptibility of Burkholderia pseudomallei from tropical northern Australia and implications for therapy of melioidosis. Int. J. Antimicrob. Agents 17:109-113. (Pubitemid 32101565)
11. Limmathurotsakul, D., and S. J. Peacock. 2011. Melioidosis: a clinical overview. Br. Med. Bull. 99:125-139.
12. Limmathurotsakul, D., et al. 2010. Increasing incidence of human melioidosis in Northeast Thailand. Am. J. Trop. Med. Hyg. 82:1113-1117.
13. Livermore, D. M., P. Y. Chau, A. I. Wong, and Y. K. Leung. 1987. β-Lactamase of Pseudomonas pseudomallei and its contribution to antibiotic resistance. J. Antimicrob. Chemother. 20:313-321. (Pubitemid 17140418)
14. Moore, R. A., D. DeShazer, S. Reckseidler, A. Weissman, and D. E. Woods. 1999. Efflux-mediated aminoglycoside and macrolide resistance in Burkholderia pseudomallei. Antimicrob. Agents Chemother. 43:465-470. (Pubitemid 29109504)
15. Sam, I. C., K. H. See, and S. D. Puthucheary. 2009. Variations in ceftazidime and amoxicillin-clavulanate susceptibilities within a clonal infection of Burkholderia pseudomallei. J. Clin. Microbiol. 47:1556-1558.
16. Schweizer, H. P. 2003. Efflux as a mechanism of resistance to antimicrobials in Pseudomonas aeruginosa and related bacteria: unanswered questions. Genet. Mol. Res. 2:48-62. (Pubitemid 38846549)
17. Simpson, A. J., et al. 1999. Comparison of imipenem and ceftazidime as therapy for severe melioidosis. Clin. Infect. Dis. 29:381-387. (Pubitemid 29380204)
18. Steward, J., et al. 2005. Comparison of gatifloxacin, moxifloxacin and ciprofloxacin for treatment of experimental Burkholderia pseudomallei infection. J. Antimicrob. Chemother. 55:523-527. (Pubitemid 40542594)
19. Suputtamongkol, Y., et al. 1994. Ceftazidime vs. amoxicillin/clavulanate in the treatment of severe melioidosis. Clin. Infect. Dis. 19:846-853. (Pubitemid 24368819)
20. Thamlikitkul, V., and S. Trakulsomboon. 2009. In vitro activity of doripenem against Burkholderia pseudomallei. Antimicrob. Agents Chemother. 53:3115-3117.
21. Walsh, A. L., and V. Wuthiekanun. 1996. The laboratory diagnosis of melioidosis. Br. J. Biomed. Sci. 53:249-253. (Pubitemid 27036156)
22. White, N. J., et al. 1989. Halving of mortality of severe melioidosis by ceftazidime. Lancet ii:697-701. (Pubitemid 19243112)
23. Wuthiekanun, V., et al. 2005. Trimethoprim/sulfamethoxazole resistance in clinical isolates of Burkholderia pseudomallei. J. Antimicrob. Chemother. 55:1029-1031. (Pubitemid 40883194)